This site is intended for healthcare professionals
News

CHMP recommends the expanded approval of Xalkori for two more uses; i. to treat certain children with anaplastic large cell lymphoma (ALCL), and ii. inflammatory myofibroblastic tumor (IMT)

Read time: 1 mins
Published:20th Sep 2022

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Xalkori

The marketing authorisation holder for this medicinal product is Pfizer Europe MA.

The CHMP adopted 2 new indications for the treatment of paediatric patients with anaplastic large cell lymphoma (ALCL) or inflammatory myofibroblastic tumour(IMT).

For information, the full indications for Xalkori will therefore be as follows: Xalkori as monotherapy is indicated for: i. The first-line treatment of adults with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC). ii. The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). iii. The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC). iv. The treatment of paediatric patients (age greater than 6 to less than 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) .vi. The treatment of paediatric patients (age greater than 6 to less than 18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumour (IMT).

Condition: ALK-positive Myofibroblastic Tumors
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.